A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs

No abstract is available for this paper.

• Publication year

  2012

• Venue

  PharmacoEconomics (Auckland)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.2165/00019053-200119070-00002PMID 11548909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gold salts in the treatment of rheumatoid arthritis. A double-blind study.

  2020cited by this paper
• Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis

  2014cited by this paper
• Kelley's Textbook of Rheumatology

  2004cited by this paper
• OMERACT 5 Economics Working Group: summary, recommendations, and research agenda.

  2001cited by this paper
• Management of rheumatoid arthritis: the historical context.

  2001cited by this paper
• Issues of consensus and debate for economic evaluation in rheumatology.

  2001cited by this paper
• Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Antimalarials for treating rheumatoid arthritis.

  2000cited by this paper
• Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.

  2000cited by this paper
• Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.

  2000cited by this paper
• Auranofin versus placebo in rheumatoid arthritis.

  2000cited by this paper
• Penicillamine for treating rheumatoid arthritis.

  2000cited by this paper
• A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

  2000cited by this paper
• Infliximab: a review of its use in the management of rheumatoid arthritis.

  2000cited by this paper
• Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.

  1999cited by this paper
• Inhibitors of tumor necrosis factor for rheumatoid arthritis.

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial.

  1999cited by this paper
• Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

  1999cited by this paper
• Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis.

  1999cited by this paper
• Modeling the lifetime costs of rheumatoid arthritis.

  1999influential reference
• Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis.

  1999cited by this paper
• Combination Therapy with Multiple Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Preventive Strategy

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Combination therapy in rheumatoid arthritis: updated systematic review.

  1998cited by this paper
• Sulfasalazine for treating rheumatoid arthritis

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• A review of cost-effectiveness analyses in rheumatology and related disciplines

  1998cited by this paper
• Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis.

  1998cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review.

  1997cited by this paper
• Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

  1997cited by this paper
• A summary of economic evaluations published in the field of rheumatology and related disciplines.

  1997cited by this paper
• Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model.

  1996cited by this paper
• Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

  1996cited by this paper
• A cost effectiveness analysis of cyclosporine in rheumatoid arthritis.

  1996cited by this paper
• A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study.

  1995cited by this paper
• The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity.

  1995cited by this paper
• ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System).

  1995cited by this paper
• Methotrexate for Rheumatoid Arthritis

  1994cited by this paper
• Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

  1994cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

  1994cited by this paper
• Methotrexate for rheumatoid arthritis : suggested guidelines for monitoring liver toxicity

  1994cited by this paper
• Methotrexate in rheumatoid arthritis. An update.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

  1994cited by this paper
• Rheumatoid arthritis : pathogenesis, assessment, outcome, and treatment

  1994cited by this paper
• Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.

  1993cited by this paper
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

  1993cited by this paper
• Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial.

  1993cited by this paper
• Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.

  1993cited by this paper
• Hydroxychloroquine Compared with Placebo in Rheumatoid Arthritis

  1993cited by this paper
• Epidemiology of the rheumatic diseases

  1993cited by this paper
• Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.

  1992cited by this paper
• Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months.

  1992cited by this paper
• Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis.

  1991cited by this paper
• Long acting drug combinations in rheumatoid arthritis: a formal overview.

  1991cited by this paper
• Ocular safety of hydroxychloroquine.

  1991cited by this paper
• Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.

  1991cited by this paper
• Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study.

  1991cited by this paper
• Methotrexate and histologic hepatic abnormalities: a meta-analysis.

  1991cited by this paper
• Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial.

  1991cited by this paper
• Disease-modifying anti-rheumatic drug therapy. An expensive therapy despite inexpensive drugs.

  1990cited by this paper
• Longterm experience with low dose weekly methotrexate in rheumatoid arthritis.

  1990cited by this paper
• Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis.

  1990cited by this paper
• Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

  1990cited by this paper
• Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients.

  1989cited by this paper
• TOXIC EFFECTS OF AZATHIOPRINE IN RHEUMATOID ARTHRITIS: A National Post‐Marketing Perspective

  1989cited by this paper
• Utilities and Quality-Adjusted Life Years

  1989cited by this paper
• Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples.

  1989cited by this paper
• Methotrexate treatment of rheumatoid arthritis: effects on radiological progression.

  1989cited by this paper
• Severe reversible interstitial pneumonitis induced by low dose methotrexate.

  1989cited by this paper
• Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment.

  1989cited by this paper
• The Quality of Well-Being Scale: Applications in AIDS, Cystic Fibrosis, and Arthritis

  1989cited by this paper
• Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.

  1989cited by this paper
• Low-dose methotrexate treatment of rheumatoid arthritis; Long-term observation of efficacy and safety

  1989cited by this paper
• The "repetitive strain injury syndrome" is referred pain from the neck.

  1989cited by this paper
• Methotrexate Pneumonitis: Bronchoalveolar Lavage Findings Suggest an Immunologic Disorder

  1989cited by this paper
• Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature.

  1988cited by this paper
• Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate.

  1988cited by this paper
• Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study.

  1988cited by this paper
• Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.

  1988cited by this paper
• The cost effectiveness of auranofin: results of a randomized clinical trial.

  1988influential reference
• Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis.

  1988cited by this paper
• A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.

  1988cited by this paper
• Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.

  1988cited by this paper
• Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis.

  1988cited by this paper
• Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy.

  1987cited by this paper
• Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study.

  1987cited by this paper
• Methods for the economic evaluation of health care programmes

  1987cited by this paper
• An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report.

  1987cited by this paper
• The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.

  1986cited by this paper
• Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

  1986cited by this paper
• Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates.

  1986cited by this paper
• Methotrexate in Rheumatoid Arthritis: An Update

  1986cited by this paper
• Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1985cited by this paper
• Practical results of treatment with disease-modifying antirheumatoid drugs.

  1985cited by this paper
• Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity.

  1985cited by this paper

• Marine-derived microbes and molecules for drug discovery

  2022cites this paper
• Rotator cuff repair in patients with inflammatory arthritis: satisfactory midterm outcomes

  2022cites this paper
• Hydroxychloroquine in Rheumatological Disorders: The Potential Buffer against Coronavirus Disease-19?

  2021cites this paper
• Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment

  2021cites this paper
• Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations.

  2018cites this paper
• Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics

  2017influential citation
• Vaccines and Biologically Produced Pharmaceuticals

  2016cites this paper
• DEMOGRAPHIC, CLINICAL CHARACTERISTICS AND DRUG PRESCRIPTION PATTERN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SOUTH INDIAN TERTIARY CARE HOSPITAL Original Article

  2016cites this paper
• DEMOGRAPHIC, CLINICAL CHARACTERISTICS AND DRUG PRESCRIPTION PATTERN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SOUTH INDIAN TERTIARY CARE HOSPITAL

  2016cites this paper
• Review of health economics modelling in rheumatoid arthritis

  2012cites this paper
• International variation in resource utilisation and treatment costs for rheumatoid arthritis

  2012cites this paper
• Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

  2012cites this paper
• Rheumatology and Rheumatoid Arthritis in the Twenty-First Century

  2012cites this paper
• Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature

  2011cites this paper
• Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample

  2011cites this paper
• Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development.

  2010cites this paper
• Pharmacoeconomic study of DMARDs in the management of rheumatoid arthritis

  2010cites this paper
• Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.

  2009cites this paper
• Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study.

  2008cites this paper
• Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis

  2007cites this paper
• Health economic issues in rheumatoid arthritis

  2006cites this paper
• The case against excessive cost sharing.

  2006cites this paper
• The Role of Antimalarials in the Exacerbation of Psoriasis

  2006cites this paper
• Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?

  2006cites this paper
• Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

  2005cites this paper
• Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro.

  2005cites this paper
• Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.

  2005cites this paper
• Management of rheumatoid arthritis.

  2004cites this paper
• A case study on rheumatoid arthritis.

  2003cites this paper
• Contribution of reactive oxygen species to cartilage degradation in rheumatic diseases: molecular pathways, diagnosis and potential therapeutic strategies.

  2003cites this paper
• Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

  2002cites this paper
• Pharmacoeconomics of long-term treatment of rheumatoid arthritis

  2002cites this paper
• Azathioprine-induced fatal macrocytic anemia in rabbits.

  2002cites this paper
• Expanding role of biologic agents in rheumatoid arthritis.

  2002cites this paper